Click here to close now.




















Welcome!

News Feed Item

Cancer Monoclonal Antibody Partnering Terms and Agreements



 

 

 

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Cancer Monoclonal Antibody Partnering Terms and Agreements

https://www.reportbuyer.com/product/1112622/Cancer-Monoclonal-Antibody-Partnering-Terms-and-Agreements.html

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in cancer monoclonal antibody partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes antibody-drug conjugate deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 350 links to online copies of actual cancer monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cancer monoclonal antibody deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract
.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with deal announcement in cancer monoclonal antibody partnering, along with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal announcement in cancer monoclonal antibody partnering, along with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since January 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus, and monoclonal antibody technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.


Report scope

Cancer Monoclonal Antibody Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.


Cancer Monoclonal Antibody Partnering Agreements includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2009
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 300 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2009


In Cancer Monoclonal Antibody Partnering Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Agreements report provides comprehensive access to available deals and contract documents for over 300 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary


Chapter 1 – Introduction

Chapter 2 – Trends in cancer monoclonal antibody dealmaking

2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Big pharma cancer monoclonal antibody dealmaking activity
2.4. Big biotech cancer monoclonal antibody dealmaking activity
2.5. Most active in cancer monoclonal antibody partnering
2.6. Cancer monoclonal antibody partnering by deal type
2.7. Cancer monoclonal antibody partnering by stage of development
2.8. Cancer monoclonal antibody partnering by cancer indication
2.9. Cancer monoclonal antibody partnering by antibody type
2.10. Disclosed deal terms for cancer monoclonal antibody partnering
2.10.1 Cancer monoclonal antibody partnering headline values
2.10.2 Cancer monoclonal antibody deal upfront payments
2.10.3 Cancer monoclonal antibody deal milestone payments
2.10.4 Cancer monoclonal antibody royalty rates

Chapter 3 – Leading cancer monoclonal antibody deals

3.1. Introduction
3.2. Top cancer monoclonal antibody deals by value

Chapter 4 – Big pharma cancer monoclonal antibody deals

4.1. Introduction

4.2. How to use big pharma partnering deals

4.3. Big pharma cancer monoclonal antibody partnering company profiles

Abbott
Abbvie
Actavis (formerly called Watson)
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Eli Lilly
Fresenius
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Takeda
Teva
UCB
Chapter 5 – Big biotech cancer monoclonal antibody deals

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech cancer monoclonal antibody partnering company profiles

Emergent BioSolutions
Genmab
LFB Group
Morphosys
PDL BioPharma
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum

Chapter 6 – Cancer monoclonal antibody dealmaking directory

6.1. Introduction

6.2. Company A-Z

6.3. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

6.4. By deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

6.5. By oncology therapy area

Oncology
Bone cancer
Brain cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Lung cancer
Non small cell lung cancer
Lymphoma
Hodgkin's lymphoma
Non Hodgkin's lymphoma
Melanoma
Metastases
Multiple myeloma
Neuroblastoma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Solid tumors
Cancer pain
Thyroid cancer
6.6. By monoclonal antibody type
Chapter 7 –Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example monoclonal antibody cancer partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Upgrades for subscription access products
Order Form – Therapy Reports
Order Form – Technology Reports

Table of figures

Figure 1: Cancer monoclonal antibody partnering since 2009
Figure 2: Big pharma – top 50 – cancer monoclonal antibody deals 2009 to 2014
Figure 3: Big pharma cancer monoclonal antibody deal frequency – 2009 to 2014
Figure 4: Big biotech – top 50 – cancer monoclonal antibody deals 2009 to 2014
Figure 5: Big biotech cancer monoclonal antibody deal frequency – 2009 to 2014
Figure 6: Active cancer monoclonal antibody dealmaking activity– 2009 to 2014
Figure 7: Cancer monoclonal antibody partnering by deal type since 2009
Figure 8: Cancer monoclonal antibody partnering by stage of development since 2009
Figure 9: Monoclonal antibody partnering by oncology target since 2009
Figure 10: Monoclonal antibody partnering by type since 2009
Figure 11: Cancer monoclonal antibody deals with a headline value – by stage of development
Figure 12: Cancer monoclonal antibody deal headline value distribution, US$million – discovery stage
Figure 13: Cancer monoclonal antibody deal headline value distribution, US$million – preclinical stage
Figure 14: Cancer monoclonal antibody deal headline value distribution, US$million – phase I stage
Figure 15: Cancer monoclonal antibody deal headline value distribution, US$million – phase II stage
Figure 16: Cancer monoclonal antibody deal headline value distribution, US$million – phase III stage
Figure 17: Cancer monoclonal antibody deal headline value distribution, US$million – regulatory stage
Figure 18: Cancer monoclonal antibody deal headline value distribution, US$million – marketed stage
Figure 19: Cancer monoclonal antibody deal headline value – median value by stage of development
Figure 20: Cancer monoclonal antibody deals with upfront payment values – by stage of development
Figure 21: Cancer monoclonal antibody deal upfront distribution, US$million – discovery stage
Figure 22: Cancer monoclonal antibody deal upfront value distribution, US$million – preclinical stage
Figure 23: Cancer monoclonal antibody deal upfront value distribution, US$million – phase I stage
Figure 24: Cancer monoclonal antibody deal upfront value distribution, US$million – phase II stage
Figure 25: Cancer monoclonal antibody deal upfront value distribution, US$million – phase III stage
Figure 26: Cancer monoclonal antibody deal upfront value distribution, US$million – regulatory stage
Figure 27: Cancer monoclonal antibody deal upfront value distribution, US$million – marketed stage
Figure 28: Cancer monoclonal antibody deal upfront value – median value by stage of development
Figure 29: Cancer monoclonal antibody deals with milestone payment – by stage of development
Figure 30: Cancer monoclonal antibody deal milestone distribution, US$million – discovery stage
Figure 31: Cancer monoclonal antibody deal milestone value distribution, US$million – preclinical stage
Figure 32: Cancer monoclonal antibody deal milestone value distribution, US$million – phase I stage
Figure 33: Cancer monoclonal antibody deal milestone value distribution, US$million – phase II stage
Figure 34: Cancer monoclonal antibody deal milestone value distribution, US$million – phase III stage
Figure 35: Cancer monoclonal antibody deal milestone value distribution, US$million – regulatory stage
Figure 36: Cancer monoclonal antibody deal milestone value distribution, US$million – marketed stage
Figure 37: Cancer monoclonal antibody deals with royalty rates
Figure 38: Cancer monoclonal antibody deal royalty rate distribution, US$million – discovery stage
Figure 39: Cancer monoclonal antibody deal royalty rate value distribution, US$million – preclinical stage
Figure 40: Cancer monoclonal antibody deal royalty rate value distribution, US$million – phase I stage
Figure 41: Cancer monoclonal antibody deal royalty rate value distribution, US$million – phase II stage
Figure 42: Cancer monoclonal antibody deal royalty rate value distribution, US$million – phase III stage
Figure 43: Cancer monoclonal antibody deal royalty rate value distribution, US$million – regulatory stage
Figure 44: Cance monoclonal antibody deal royalty rate value distribution, US$million – marketed stage
Figure 45: Cancer monoclonal antibody deal royalty value – median value by stage of development
Figure 46: Top cancer monoclonal antibody deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Figure 49: Deal type definitions
Figure 50: Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets



Read the full report:
Cancer Monoclonal Antibody Partnering Terms and Agreements

https://www.reportbuyer.com/product/1112622/Cancer-Monoclonal-Antibody-Partnering-Terms-and-Agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
SYS-CON Events announced today that Micron Technology, Inc., a global leader in advanced semiconductor systems, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Micron’s broad portfolio of high-performance memory technologies – including DRAM, NAND and NOR Flash – is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of tech...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies leverage disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advance...
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Trel...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
Everyone talks about continuous integration and continuous delivery but those are just two ends of the pipeline. In the middle of DevOps is continuous testing (CT), and many organizations are struggling to implement continuous testing effectively. After all, without continuous testing there is no delivery. And Lab-As-A-Service (LaaS) enhances the CT with dynamic on-demand self-serve test topologies. CT together with LAAS make a powerful combination that perfectly serves complex software developm...